We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Bristol-Myers Squibb (BMY - Free Report) closed at $52.81 in the latest trading session, marking a -0.34% move from the prior day. This change lagged the S&P 500's daily loss of 0.25%. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq lost 0.53%.
Heading into today, shares of the biopharmaceutical company had lost 12.8% over the past month, lagging the Medical sector's loss of 1.06% and the S&P 500's loss of 2.35% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. This is expected to be February 4, 2019. On that day, BMY is projected to report earnings of $0.84 per share, which would represent year-over-year growth of 23.53%. Meanwhile, our latest consensus estimate is calling for revenue of $5.99 billion, up 9.85% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.84 per share and revenue of $22.58 billion. These totals would mark changes of +27.57% and +8.68%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for BMY. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 6.62% higher within the past month. BMY is currently sporting a Zacks Rank of #1 (Strong Buy).
Valuation is also important, so investors should note that BMY has a Forward P/E ratio of 13.79 right now. This represents a discount compared to its industry's average Forward P/E of 14.74.
We can also see that BMY currently has a PEG ratio of 1.49. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BMY's industry had an average PEG ratio of 2.01 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
Bristol-Myers Squibb (BMY - Free Report) closed at $52.81 in the latest trading session, marking a -0.34% move from the prior day. This change lagged the S&P 500's daily loss of 0.25%. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq lost 0.53%.
Heading into today, shares of the biopharmaceutical company had lost 12.8% over the past month, lagging the Medical sector's loss of 1.06% and the S&P 500's loss of 2.35% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. This is expected to be February 4, 2019. On that day, BMY is projected to report earnings of $0.84 per share, which would represent year-over-year growth of 23.53%. Meanwhile, our latest consensus estimate is calling for revenue of $5.99 billion, up 9.85% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.84 per share and revenue of $22.58 billion. These totals would mark changes of +27.57% and +8.68%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for BMY. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 6.62% higher within the past month. BMY is currently sporting a Zacks Rank of #1 (Strong Buy).
Valuation is also important, so investors should note that BMY has a Forward P/E ratio of 13.79 right now. This represents a discount compared to its industry's average Forward P/E of 14.74.
We can also see that BMY currently has a PEG ratio of 1.49. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BMY's industry had an average PEG ratio of 2.01 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.